Snake antivenoms: Adverse reactions and production technology

Journal of Venomous Animals and Toxins Including Tropical Diseases

Volumn 15, Issue 1, 2009, Pages 2-18

  Morais, Victor M ^a,b   Massaldi, H ^a  

^a DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^b Universidad de la Republica Instituto de Higiene   (Uruguay)

Author keywords

Anaphylactic reaction; Complement system activation; Endotoxins; Snake antivenom

Indexed keywords

ANTISERUM; BATROXOBIN; COMPLEMENT; ENDOTOXIN; FLAVONOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN FRAGMENT; NEUTRALIZING ANTIBODY; PYROGEN; SNAKE VENOM; SNAKE VENOM ANTISERUM; STEROID; TERPENE;

ACCIDENT; ANAPHYLAXIS; ANTIGEN ANTIBODY COMPLEX; ARTHROPATHY; CLINICAL EVALUATION; COMPLEMENT ACTIVATION; DRUG COST; DRUG DETERMINATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG QUALITY; FEVER; HUMAN; IMMUNE RESPONSE; KIDNEY INJURY; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN AGGREGATION; PROTEINURIA; REVIEW; SNAKEBITE; VACCINATION;

ANIMALIA;

EID: 65749089971     PISSN: 16789199     EISSN: 16789199     Source Type: Journal    
DOI: 10.1590/S1678-91992009000100002     Document Type: Review

References (89)

1. Chippaux JP, Goyffon M. Venoms, antivenoms and inmunotherapy. Toxicon. 1998;36(6):823-846
2. Theakston RDG, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon. 2003;41(5):541-557
3. Wilde H, Thipkong P, Sitprija V, Chaiyabutr N. Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis. Ann Intern Med. 1996;125(3):233-236
4. Calmette A. Contribution a l̀etude du venin des serpents. Immunisation des animaux et traitement de l' envenimation. Ann Inst Pasteur. 1894;8:275-291
5. Calmette A. Contribution à l'ètude des venins, des toxins et des serums antitoxiques. Ann Inst Pasteur. 1895;9:225-251
6. Hawgood B. Doctor Albert Calmette 1863-1933: founder of antivenomous serotherapy and of antituberculous BCG vaccination. Toxicon. 1999;379):1241-1258
7. Clark RF, McKinney PE, Chase PB, Walter FG. Immediate and delayed allergic reactions to Crotalidae Polyvalent Immune Fab (ovine) antivenom. Ann Emerg Med. 2002;39(6):671-677
8. Dart RC, Mcnally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emerg Med. 2001;37(2):181-188
9. Otero-Patino R, Cardozo J, Higashi H, Nuñez V, Diaz A, Toro M, García M, Sierra A, García LF, Moreno A, Medina M, Castañeda N, Silva-Diaz JF, Murcia M, Cardenas SY, Dias da Silva WD. A randomized, blinded, comparative trial of one pepsin-digested and two whole IgG antivenoms for Bothrops snake bites i Uraba, Colombia. The Regional Group of Antivenom Therapy Research (REGATHER). Am J Trop Med Hyg. 1998;58(2):183-189 (Pubitemid 28096224)
10. Harms AJ. The purification of antitoxic plasmas by enzyme treatment and heat denaturation. Biochem J. 1948;42(3):390-397
11. Gutiérrez JM, Higashi HG, Wen FH, Burnouf T. Strengthening antivenom production in Central and South American public laboratories: Report of a workshop. Toxicon. 2007;49(1):30-35
12. Rojas G, Jiménez JM, Gutierrez JM. Caprylic acid fractionation of hyperinmune horse plasma: description of a single procedure for antivenom production. Toxicon. 1994;32(3):351-363
13. Raweerith R, Ratanabanangkoon K. Fractionation of equine antivenom using caprylic acid precipitation in combination with cationic ion-exchange chromatography. J Immunol Meth. 2003;282(1-2):63-72.
14. 2 preparations against European viper venoms and the tetanus toxin. Toxicon. 1997;35(3):411-422
15. Raw I, Guidolin R, Higashi H, Kelen E. Antivenins in Brazil: preparation. In: Tu AT (editor). Handbook of natural toxins. Vol.5. New York: Marcel Dekker; 1991. p.557-583
16. Jadhav SS, Kapre SV. Antivenom producion in India. In: Tu AT (editor). Handbook of natural toxins. vol.5. New York: Marcel Dekker; 1991, p. 584-608.
17. Abbas AK, Lichtman AH, Pober JS (editors). Cellular and molecular immunology. 4th ed. Philadelphia: WB Sanders Co.; 2000.
18. Abbas AK, Litchman AH. Immediate Hypersensitivity. In: Abbas AK, Litchman AH (editors). Cellular and molecular immunology. 5th ed. Philadelphia: Saunders Elsevier Science; 2003.
19. nd ed. Florida: CRC Press; 2004.
20. Morais V, Massaldi H. Economic evaluation of snake antivenom production in the public system. J Venom Anim Toxins incl Trop Dis. 2006;12(3):497-511.
21. Steinbuch M, Audran R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys. 1969;134(2):279-284
22. Gutiérrez JM, Rojas E, Quesada L, León G, Nuñez J, Laing GD, Sasa M, Renjifo JM, Nasidi A, Warrell DA, Theakston RDG, Rojas G. Pan-African polyspecific antivenom produced by caprylic acid purification of horse IgG: an alternative to the antivenom crisis in Africa. Trans R Soc Trop Med Hyg. 2005;99(6):468-475 (Pubitemid 40521345)
23. Saetang T, Treamwattana N, Suttijitpaisal P, Ratanabanangoon K. Quantitative comparison on the refinement of horse antivenom by salt fractionation and ion-exchange chromatography. J Chromatog B. 1997;700(1-2):233-239
24. Gutiérrez JM, Lomonte B, León G, Rucavado A, Chaves F, Angulo Y. Trends in snakebite envenomation therapy: Scientific, technological and Public Health considerations. Curr Pham Des. 2007;13(28):2935-2950
25. Krifi MN, El Ayeb M. Dellagi K. The improvement and standardization of antivenom production in developing countries: comparing antivenom quality, therapeutical efficiency, and cost. J Venom Anim Toxins. 1999;5(2):128-141
26. Chotwiwatthanakun C, Pratanaphon R, Akesowan S, Sriprapat S, Ratanabanangkoon K. Production of potent polyvalent antivenom against three elapid venoms using a low dose, low volume, multi-site immunization protocol. Toxicon. 2001;39(10):1487-1494
27. Sriprapat S, Aeksowan S, Sapsutthipas S, Chotwiwatthanakun C, Suttijitpaisal P, Pratanaphon R, Khow O, Sitprija V, Ratanabanangkoon K. The impact of a low dose, low volume, multi-site immunization on the production of therapeutic antivenoms in Thailand. Toxicon. 2003;41(1):57-64.
28. Ferreira Junior RS, Nascimento N, Couto R, Alves JB, Meira DA, Barraviera B. Laboratory evaluation of young ovines inoculated with natural or 60Co-irradiated Crotalus durissus terrificus venom during hyperimmunization process. J Venom Anim Toxins incl Trop Dis. 2006;12(4):620-631
29. Oussedik-Oumehdi H, Laraba-Djebari F. Irradiated Cerastes cerastes venom as a novel tool for immunotherapy. Immunopharmacol Immunotoxicol. 2008;30(1):37-52.
30. Jones RG, Corteling RL, Bhogal G, Landon J. A novel Fab based antivenom for the treatment of the mass bee attacks. Am J Trop Med Hyg. 1999;61(3):361-366
31. 2. Results of a clinical trial in northern Cameroon. Am J Trop Med Hyg. 1999;61(6):1017-1018
32. Fernandez I, Takeara HA, Mota I. Isolation of IgG(T) from hyperimmune horse anti-snake venom serum: its protective ability. Toxicon. 1991;29:1373-1379
33. Fernandez I, Takeara HA, Santos CR, Cormont F, Latinne D, Bazin H, Mota I. Neutralization of bothropic and crotalic venom toxic activities by IgG(T) and IgGa subclases isolated from immune horse serum. Toxicon. 1997;35(6):931-936
34. Fernández I, Lima EX, Takehara HA, Moura-da-Silva AM, Tanjoni I, Gutierrez JM. Horse IgG isotypes and cross-neutralization of two snake antivenoms produced in Brazil and Costa Rica. Toxicon. 2000;38(5):633-644
35. Pope CG. Disaggregation of proteins by enzymes. Br J Exp Path. 1938;19:245-251
36. Pope CG. The action of proteolyitic enzymes on the antitoxin and proteins in inmune sera: I True digestion of the proteins. Br J Exp Path. 1939;20:132-149
37. Pope CG. The action of proteolyitic enzymes on the antitoxin and proteins in inmune sera: II Heat denaturation after partial enzyme action. Br J Exp Path. 1939;20:201-212
38. Sjostrom L, Al-Abdulla I, Rawat S, Smith D, Landon J. A comparation of ovine and equine antivenoms. Toxicon. 1994;32(4):427-433
39. Ariaratnam CA, Meyer WP, Perera G, Eddleston M, Kuleratne AM, Attapattu W, Sheriff R, Richards AM, Theakston RDG, Warrel DA. A new monospecific ovine Fab fragment antivenom for the treatment of envenoming by the Sri Lankan Russell's viper (Daboia russelli russelli): a preliminary dose-finding and pharmacokinetics study. Am J Trop Med Hyg. 1999;61(2):259-265
40. Harrison RA, Hasson SS, Harmsen M, Laing GD, Conrath K, Theakston RDG. Neutralization of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. Toxicon. 2006;47(3):364-368 (Pubitemid 43294466)
41. Herrera M, León G, Segura A, Meneses F, Lomonte B, Chippaux JP, Gutiérrez JM. Factors associated with adverse reactions induced by caprylic acid-fractionated whole IgG preparations: comparison between horse, sheep and camel IgGs. Toxicon. 2005;46(7):775-781
42. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharm. 2006;6(4):535-542
43. Ferreira RN, Machado de Avila RA, Sanchez EF, Maria WS, Molina F, Granier C, Chávez-Olórtegui C. Antibodies against synthetic epitopes inhibit the enzymatic activity of mutalysin II, a metalloproteinase from bushmaster snake venom. Toxicon. 2006;48(8):1098-1103
44. Rafael A, Tanjoni I, Fernandes I, Moura-da-Silva AM, Furtado MF. An alternative method to access in vitro the hemorrhagic activity of snake venoms. Toxicon. 2008;51(4):479-487
45. Sánchez EE, García C, Pérez JC, de La Zerda SJ. The detection of hemorrhagic proteins in snake venoms using monoclonal antibodies against Virginia opossum (Didelphis virginiana) serum. Toxicon. 1998;36(10):1451-1459
46. Stábeli RG, Magalhães LM, Selistre-de-Araujo HS, Oliveira EB. Antibodies to a fragment of the Bothrops moojenii-amino acid oxidase cross-react with snake venom components unrelated to the parent protein. Toxicon. 2005;46(3):308-317
47. Tamarozzi MB, Soares SG, Marcussi S, Giglio JR, Barbosa JE. Expression of recombinant human antibody fragments capable of inhibiting the phospholipase and myotoxic activities of Bothrops jararacussu venom. Biochim Biophys Acta. 2006;1760(9):1450-1457 (Pubitemid 44374213)
48. Harrison RA, Wuster W, Theakston RGD. The conserved structure of snake venom toxins confers extensive immunological cross-reactivity to toxin-specific antibody. Toxicon. 2003;41(4):441-449
49. Tanjoni I, Butera D, Bento L, Della-Casa M, Marques R, Takehara H, Gutiérrez JM, Fernández I, Moura da Silva A. Snake venom metalloproteinases: structure/function relationships studies using monoclonal antibodies. Toxicon. 2003;42(7):801-808
50. Colombini M, Fernandes I, Cardoso DF, Moura-da-Silva AM. Lachesis muta muta venom: immunological differences compared with Bothrops atrox venom and importance of specific antivenom therapy. Toxicon. 2001;39(5):711-719
51. Galán J, Sánchez E, Rodríguez-Acosta A, Pérez J. Neutralization of venoms from two Souther Pacific rattlesnakes (Crotalus helleri) with comercial antivenoms and endothermic animal sera. Toxicon. 2004;43(7):791-799
52. Lizano S, Domont G, Perales J. Natural phospholipase A2 myotoxin inhibitor proteins from snakes, mammals and plants. Toxicon. 2003;42(8):963-977 (Pubitemid 38201495)
53. Peréz J, Sánchez E. Natural protease inhibitors to hemorrhagins in snake venoms and their potential use in medicine. Toxicon. 1999;37(5):703-728
54. Nuñez V, Otero R, Barona J, Fonnegra R, Jiménez S, Osorio R, Quintana J, Díaz A. Inhibition of the toxic effects of Lachesis muta, Crotalus durissus cumanensis and Micrurus mipartitus snake venoms by plant extracts. Pharm Biol. 2004;42(1):49-54.
55. Mors W, Nacimento MC, Pereira BMR, Pereira NA. Plant natural products active against snake bite, the molecular approach. Phytochemistry. 2000;55(6):627-642
56. Fortes-Dias C. Endogenous inhibitors of snake venom phospholipases A2 in the blood plasma of snakes. Toxicon. 2002;40(5):481-484
57. Jurgilas P, Neves-Ferreira A, Domont G, Perales J. PO41, a snake venom metalloproteinase inhibitor isolated from Philander opossum serum. Toxicon. 2003;42(6):621-628
58. Neves-Ferreira A, Cardinale N, Rocha S, Perales J, Domont G. Isolation and caracterization of DM40 and DM43, two snake venom metalloproteinase inhibitors from Didelphis marsupialis serum. Biochim Biophys Acta. 2000;1474(3):309-320
59. Surza L, Rocha G, Lomonte B, Neves-Ferreira A, Trugilho M, Junqueira-de-Azevedo I, Ho P, Domont G, Gutiérrez JM, Perales J. Functional analysis of DM64, an antimyotoxic protein with immunoglobulin-like structure from Didelphis marsupialis serum. Eur J Biochem. 2002;269:6052-6062
60. Thwin M, Gopalakrishnakone P. Snake envenomation and protective natural endogenous proteins: a mini review of the recent developments (1991 - 1997). Toxicon. 1998;36(11):1471-1482
61. th. ed. Espana: Mc Graw Hill; 2002.
62. th. ed. Philadelphia: Elsevier Science Saunders; 2003.
63. García M, Monge M, León G, Lizano S, Segura E, Solano G, Rojas G, Gutiérrez JM.. Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent anti-venom used in snakebite envenomation. Biologicals. 2002;30(2):143-151 (Pubitemid 36268642)
64. Otero R, Gutiérrez JM, Rojas G, Nuñez V, Díaz A, Miranda E, Uribe AF, Silva JF, Ospina JG, Medina Y, Toro MF, García ME, León G, García M, Lizano S, de La Torre J, Márquez J, Mena Y, González N, Arenas LC, Puzón A, Blanco N, Sierra A, Espinal M, Arboleda M, Jiménez JC, Ramírez P, Díaz M, Guzmán MC, Barros J, Henao S, Ramírez A, Macea U, Lozano R. A randomized, blinded clinical trial of two antivenoms , prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites Colombia: correlation between safety and biochemical characteristics of antivenoms. Toxicon. 1999;37(6):895-908.
65. Otero R, León G, Gutiérrez JM, Rojas G, Toro MF, Barona J, Rodríguez V, Díaz A, Nuñez V, Quintana JC, Ayala S, Mosquera D, Conrado L, Fernández D, Arroyo Y, Paniagua C, López M, Ospina C, Alzate C, Fernández J, Meza J, Silva J, Ramírez P, Fabra P, Ramírez E, Córdoba E, Arrieta A, Warrell DA, Theakston RDG. Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without β-propiolactone, in the treatment of Bothrops asper bites in Colombia. Trans R Soc Trop Med Hyg. 2006;100(12):1173- 1182 (Pubitemid 44464013)
66. León G, Lomonte B, Gutiérrez JM. Anticomplementary activity of equine whole IgG antivenoms: comparison of three fractionation protocols. Toxicon. 2005;45(1):123-128
67. Morais V, Massaldi H. Effect of pepsin digestion on the antivenom activity of equine immunoglobulins. Toxicon. 2005;46(8):876-882
68. 2 fragments in high yield for serum. J Immunol Methods. 2002;263(1-2):57-74.
69. Jones RG, Landon J. A protocol for enhanced pepsin digestion a step by step method for obtained pure antibody fragments in high yield from serum. J Immunol Methods. 2003;275(1-2):239-250
70. Rojas G, Espinoza M, Lomonte B, Gutiérrez JM. Effect of storage temperature on the stability of the liquid polyvalent antivenom produced in Costa Rica. Toxicon. 1990;28(1):101-105
71. Silverstein AM. Clemens Freiherr von Pirquet: Explaining immune complex disease in 1906. Nat Immunol. 2000;1:453-455
72. 2 polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation of muscle tissue, and potential for induction of adverse reactions. Toxicon. 2001;39(6):793-801.
73. Silva de Freitas S, Machado RL, De Arruda EJ, Costapinto C, Alves Bueno S. Endotoxin removal from solutions of F(ab-)2 fragments of equine antibodies against snake venom using macroporous chitosan membrane. J Memb Sci. 2004;234(1-2):67-73.
74. Petsch D, Anspach FB. Endotoxin removal from protein solutions. J Biotechnol. 2000;76(2-3):97-119.
75. Brunn GJ, Platt JL. The etiology of sepsis: turned inside out. Trends Mol Med. 2006;12(1):10-16
76. Erridge C, Bennett-Guerrero E, Poxton I. Structure and function of lipopolysaccharides. Microbes Infect. 2002;4(8):837-851
77. Fang H, Wei J, Yu Y. In vivo studies of endotoxin removal by lysine-cellulose adsorbents. Biomaterials. 2004;25(23):5433-5440
78. Rangel-Frausto MS. Sepsis: still going strong. Arch Med Research. 2005;36(6):672-681
79. Victor V, Rocha M, De La Fuente M. Immune cells: free radicals and antioxidants in sepsis. Int Inmunopharmacol. 2004;4(3):327-347
80. Machado RL, De Arruda EJ, Santana CC, Bueno SMA. Evaluation of a chitosan membrane for removal of endotoxin from human IgG solutions. Process Biochem. 2006;41(11):2252-2257
81. Massaldi H, Morais V. Evolution of endotoxin contamination during production of a therapeutic serum. PDA J Pharm Sci Technol. 2007;61(5) :375-382
82. Anspach FB. Endotoxin removal by affinity sorbents. J Biochem Biophys Methods. 2001;49(1-3):665-81.
83. Hirayama C, Sakata M. Chromatographic removal of endotoxin from protein solutions by polymer particles. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;781(1-2):419-432
84. Yamamoto K, Matsuda M, Hayama M, Sutagawa J, Tanaka S, Kohori F, Sakai K. Evaluation of the activity of endotoxin trapped by a hollow-fiber dialysis membrane. J Memb Sci. 2006;272(1-2):211-216
85. Acconci C, Legallais C, Vijayalakshmi M, Alves S. Depyrogenation of snake antivenom serum solutions by hollow fiber-based pseudobioaffinity filtration. J Memb Sci. 2000;173(2):235-245
86. Cheng A, Winkel K, Bawaskar HS, Bawaskar PH. Call for global snake-bite control and procurement funding. Lancet. 2001;357(9262):1132-1133
87. Laing GD, Renjifo JM, Ruiz F, Harrison RA, Nasidi A, Gutierrez JM, Rowley PD, Warrell DA, Theakston RDG. A new Pan African polyespecific antivenom developed in response to the antivenom crisis in Africa. Toxicon. 2003;42(1):35-41.
88. Laloo D, Theakston D, Warrell D. The African challenge. Lancet. 2002;359(9316):1527.
89. Theakston RDG, Warrell DA. Crisis of snake antivenom supply for Africa. Lancet. 2000;356(9247):2104.